Research

Communication and Advancement Awards Report Fiscal Year 2001
Medical Center Area
Medicine
Pediatrics

Primary Total: $3,194,923.
 Collaborative Total: $3,814,879.

ABE FOSSON JR
Developmental Evaluation Services, (464046), KY Department for Public Health, $30,000.00

ABE FOSSON JR
Arlington Elementary School Center, (464095), Lexington Fayette County Health Department, $16,000.00

BRADLEY KELLER
RFA - Screening Technology for Mouse Embryo CV Phenotype HL-99-010, (464266), Natl Heart Lung and Blood Institute, $394,897.00

BRADLEY KELLER
Biomechanical Adaptation of the Embyonic Myocardium to Chronic Hemodynamic Alterations, (464357), NATO Scientific Affairs Division, $18,000.00

BRADLEY KELLER/JONATHAN SATIN/ELIZABETH SCHRODER/KIMIMASA TOBITA
Adaptive Heterogeneity of Embryonic Chick Myocardium - Revised Proposal, (464699), Natl Heart Lung and Blood Institute, $335,951.00

BRYAN HALL
Genetic Services, (463976), KY Department for Public Health, $262,000.00

CAROL ELAM/DONNA GRIGSBY
* PRIME - Community Responsive Curriculum Project, (463720), American Medical Student Association, $1,900.00

DAVID KAETZEL/MARGARET BRUCE
* PDGF Gene Regulation by Vitamins A & D in Alveolization, (464230), Natl Heart Lung and Blood Institute, $215,970.00

ELIZABETH JACKSON
Pilot Trial in Young Patients with IGA Nephropathy, (462558), Natl Institute Diabetes & Digestive & Kidney, $945.00

ELIZABETH SCHRODER/BRADLEY KELLER
Functional Maturation of Embryonic Myocardium, (464780), Natl Heart Lung and Blood Institute, $47,348.00

HATIM OMAR
Winburn Adolescent Health Care, (464762), Lexington Fayette County Health Department, $4,500.00

HATIM OMAR
Tates Creek High School Wellness Center, (464761), Lexington Fayette County Health Department, $10,000.00

HATIM OMAR
Young Parents Program, (463979), KY Department for Public Health, $325,700.00

HEINRICH WERNER
A Natural History Study of Neonates with Enteroviral Sepsis Syndrome, (464062), ViroPharma Inc, $1,575.00

HEINRICH WERNER
A Multi Center, Prospective, Blinded, Randomized Trial Evaluating the Safety and Efficacy of Infasurf (Calfactant) in Patients with Respiratory Failure, (463940), ONY Inc, $2.00

J MOORE
PATH-I (PEDIATRIC USE OF AMLODIPINE IN THE TREATMENT OF HYPERTENSION-1). (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Efficacy and Safety of Amlodipine in the Treatment of Hypertension in Children) , (463489), Pfizer Inc, $24,735.00

JACKIE SAMPERS
BASICS: Baby Awareness and Support Through Interactive Computer Systems, (463824), Department of Education, $197,178.00

JACKIE SAMPERS
First Steps to the Development of a Neonatal Developmental Training Institute, (464213), March of Dimes Birth Defects Fdtn, $21,475.00

JAMSHED KANGA
Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmozyme, (429780), Genentech Inc, $14,200.00

JAMSHED KANGA
A Study to Determine Variability of a 6-Minute Walk Test in Cystic Fibrosis (CF) Subjects with Advanced Lung Disease, (462799), Genentech Inc, $1,098.00

JAMSHED KANGA/MICHAEL ANSTEAD
Cystic Fibrosis Center Program, (464157), Cystic Fibrosis Fdtn, $67,493.00

JEFFREY MOSCOW
Children's Hemophilia Program, (463945), KY Commission for Children with Special Health, $15,000.00

JEFFREY MOSCOW
Sickle Cell Screening, (463896), KY Department for Public Health, $7,200.00

JEFFREY MOSCOW
Comprehensive Hemophilia Treatment Center, (464388), KY Health Services Cab, $2,000.00

JEFFREY MOSCOW
Adult & Pediatric Hemphilia Treatment Center, (464700), KY Commission for Children with Special Health, $16,250.00

JENS GOEBEL
CV118-028 Study of Blood Pressure Reduction with Fosinopril in Children and Adolescents, (464896), Bristol Myers Squibb Company, $2.00

JENS GOEBEL
Molecular Mechanisms of Immunomodulation Affected by Daclizumab, (464403), Roche Pharmaceutical Research Associates Inc, $4,400.00

JENS GOEBEL
Impact of Humanized Anti-CD25 Antibody on Interleukin 2 Receptor, (463576), Roche Laboratories, $5,718.00

JENS GOEBEL
A Dose Ranging, Safety and Tolerability Trial of Felodipine ER in Pediatric Patients: A Multicenter Double-Blind, Placebo-Controlled, Randomized, Parallel Group Trial with an Optional Open-Label Extension, (463391), AstraZeneca, $912.00

JENS GOEBEL
The Pediatric Use of Amlodipine in the Treatment of Hypertension: A Population Pharmacokinetic Trial (PATH-2), (463622), Pfizer Inc, $139.00

JENS GOEBEL
A Multicenter, Prospective, Randomized, Double-Blind, Controlled Clinical Trial of SYNSORB Pk in Children with E. Coli Associated Hemolytic Uremic Syndrome HUS, (462751), Long Island Jewish Medical Center, $733.00

JENS GOEBEL
SYNSORB Pk Phase III Clinical Trial Prevention of HUS in Children, (462679), Synsorb Biotech Inc, $2,579.00

JOHN FOWLKES
The Physiology of IGFBP-degrading Proteinases in Bone, (462976), Natl Institute Diabetes & Digestive & Kidney, $230,146.00

KATHRYN THRAILKILL
Kabi International Growth Study, (460576), Pharmacia & Upjohn Inc, $3,300.00

KATHRYN THRAILKILL
Diabetes Prevention Trial - Type 1 (DPT-1), (460554), Univ of Miami School of Medicine, $3,660.00

KATHRYN THRAILKILL
Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: Trial, (462611), Pfizer Inc, $9,915.00

KATHRYN THRAILKILL
Long Term Safety of Inhaled Human Insulin: Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials Protocol # 217-111, (463339), Pfizer Inc, $21,139.00

KATHRYN THRAILKILL
The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers with Turner Syndrome, (463047), Eli Lilly and Company, $2,150.00

KATHRYN THRAILKILL
Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Children Ages 6-11 Years with Type 1 Diabetes Mellitus: A Three-month, Outpatient, Parallel Comparative Trial. Protocol No. A2171009, (463667), Pfizer Inc, $22,017.00

KATHRYN THRAILKILL
Metabolic Services, (463899), KY Department for Public Health, $210,700.00

KATHRYN THRAILKILL
Norditropin and Norditropin cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children with Growth Hormone Deficiency, (464534), Novo Nordisk Pharmaceuticals Inc, $13,272.00

KATHRYN THRAILKILL
A 24-Week Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus, (464316), Smith Kline Beecham, $2.00

KATHRYN THRAILKILL
Celiac Disease inType I Diabetes: Growth and Bone Mineralilzation, (464701), Duke Univ Medical Center, $4,125.00

LYNN CAMPBELL
Comparison of the Safety, Tolerability and Immunogenicity of P32 Process Upgrade Varicella Vaccine (PUVV) to P31 PUVV When Each is Administered Concomitantly with MMRII to Subjects 12 to 23 Months of Age Protocol 050-01, (463887), Merck and Company Inc, $20,158.00

MARTHA GREENWOOD
Children's Cancer Group, (464770), Natl Childhood Cancer Fdtn, $2.00

MARTHA GREENWOOD
Children's Cancer Group, (462992), Natl Childhood Cancer Fdtn, $56,186.00

MICHAEL ANSTEAD
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Trial of Azithromycin inPatients with CF, Chronically Infected with Pseudomonas Aeruginosa, (464723), Cystic Fibrosis Fdtn, $2.00

MICHAEL ANSTEAD/DENNIS DOHERTY
Antiinflammatory Effect of Azithromycin in Cystic Fibrosis, (463224), American Lung Assoc, $1,451.00

NIRMALA DESAI
Neurological Outcome and Pre-emptive Analgesia Neonates (NEOPAIN) Trial, (463903), Maryland Medical Research Institute, $32,659.00

NIRMALA DESAI
Neurologic Outcomes & Pre-Emptive Analgesia in Neonates (NEOPAIN) Trial, (464191), Arkansas Children's Hospital Research Institute, $11,810.00

PATRICK MCNAMARA/JEFFREY MOSCOW
* Transport Gene Expression and Drug Accumulation in Milk, (464604), Natl Institute of Child Health and Human Develop, $273,244.00

PATRICK MCNAMARA/NIRMALA DESAI/ROBERT KUHN
* ASingle-Dose Milk Transfer Study of Hydromorphone Hydrochloride Following Intranasal Administration in Healthy Human Volunteers, (463851), Inhalation Technology Inc, $37,842.00

PETER WONG
Regional Pediatrics, (463893), KY Department for Public Health, $130,000.00

PETER WONG
Comparison of the Safety, Tolerability and Immunogenicity of Process Upgrade Varicella Vaccine Made with New Stabilizer When Administered Concomitantly with MMRII, (463390), Merck and Company Inc, $12,001.00

PETER WONG
Pediatric Immunizations, (463897), KY Department for Public Health, $35,000.00

STEFAN KIESSLING/JENS GOEBEL
Ex-Vivo T Cell Responses to Presumed Antigen in a Patient With Systemic Eosinophilia Associated With Minocycline Therapy, (464383), American Academy of Pediatrics, $2,000.00

SUSAN POLLACK
* Pediatric and Adolescent Injury Prevention Program, (464143), KY Department for Public Health, $91,000.00

THOMAS PAULY
Infant Intensive Care, (463894), KY Department for Public Health, $475,000.00

THOMAS PAULY
A Randomized, Multicenter Comparison of Curosurf and Survanta in the Treatment of Established Neonatal Respiratory Distress Syndrome, (462483), Cato Research/Dey Laboratories, $9,898.00

THOMAS YOUNG
Tates Creek Elementary School Center, (464022), Lexington Fayette County Health Department, $8,000.00

THOMAS YOUNG
Harrison Elementary School Center, (464325), Lexington Fayette County Health Department, $31,200.00

THOMAS YOUNG
Johnson Elementary School Center, (464249), Lexington Fayette County Health Department, $16,000.00

WILBURN SMITH
Genentech National Cooperative Growth Study Post Marketing Surveillance Program for Protropin/Somatrem and Nutropin/ Somatropin, (429197), Genentech Inc, $5,100.00


* Cross-referenced accounts where the project director/s are affiliated with more than one department, college or center
Information Systems
Questions:
 Deborah Davis,  Office of Sponsored Projects Administration, 112 Kinkead Hall, 0057, 257-8311

UK Awards Home    Research    University of Kentucky